11:57 AM EST - Acasti Pharma : reports the highlights of its financial results for the fiscal year ended February 29, 2012. Acasti generated revenues of $10,000 from its first sales of its Medical Food product, Onemia, and $116,000 from a research contract it has conducted for Neptune compared to revenues of $28,000 from research it was conducting for Neptune during the corresponding period of 2011. Adjusted EBITDA was negative $4,481,000, compared to negative $2,255,000 obtained during the corresponding period of 2011. Net loss amounted to $6,501,000, or $0.10 per share, compared to $3,008,000, or $0.06 per share, for the corresponding period of 2011. Acasti Pharma
shares V.APO are trading down $0.03 at $2.38.
